Ann: Prana provides regulatory update for PBT2-PBT.AX, page-47

When somebody tries to create suspicion of Prana holding back info which could be the reason for the hold, then there is no more relevant example than OMER. Same year, same disease and the reason was animal tests. In the OMER case they even shut down a running clinical trial. Like Prana OMER stated they had seen no problems in human trials. A difference is that Prana has exposed more patients and longer trials than OMER to back their statement of no serious problems in humans.
A more suspect example is Teva. They paid $3.5B for Auspex to get their HD drug SD809 which had successfully completed Phase3 trials. Effects are similar to an already approved drug, yet the FDA put a hold on it.
If you know anything about Prana's history, you know they have enough cash to progress. They can raise over the period of the trial, the HSG will possibly assist again, monies spent in Aus will be boosted by govt and if the trial is approved, then perhaps a partner could be interested. Raising during the last trials did not hold the price rise back much, if at all.